Is Natco Pharma (NATCOPHARM) overvalued or fairly valued?

MarketChacha shows Natco Pharma's valuation in context — a forward P/E of about 17.5, a price-to-book of about 1.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Natco Pharma's revenue?

Natco Pharma reported revenue of ₹3,595 Cr for FY2026, with net profit of ₹1,282 Cr, per official filings.

What is the share price of Natco Pharma (NATCOPHARM)?

Natco Pharma last traded at ₹828.65 (-1.2% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Natco Pharma

NATCOPHARM · NSE · Pharma · India

Snapshot

TickerNATCOPHARM

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

HeadquartersHyderabad, India

Websitewww.natcopharma.co.in

Filings tracked9

About Natco Pharma

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Who owns it

Promoters51.0%
Institutions12.8%
Public & other36.2%

75 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend26.4% → 34.8%

Margin has expanded by about 8.4 points — the business is getting more profitable.

Growth qualityrev 11% · PAT 19%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹3,589 Cr · EPS 47.37

Est. earnings growth +12.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Revenue (FY2026)

₹4,078 Cr

Net margin

34.8%

Revenue CAGR (3y)

+14.6%

Profit CAGR (3y)

+25.6%

Net profit (FY2026)

₹1,419 Cr

Ask MarketChacha about NATCOPHARM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹4,078 Cr	₹1,419 Cr	34.8%
FY2025	₹4,430 Cr	₹1,885 Cr	42.6%
FY2024	₹3,999 Cr	₹1,388 Cr	34.7%
FY2023	₹2,707 Cr	₹715 Cr	26.4%

Quarterly

Period	Revenue	Net profit	Net margin
Q4 FY26	₹739 Cr	₹268 Cr	36.2%
Q3 FY26	₹647 Cr	₹152 Cr	23.4%
Q2 FY26	₹1,363 Cr	₹518 Cr	38.0%
Q1 FY26	₹1,329 Cr	₹481 Cr	36.2%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Notice Of 43Rd Annual General Meeting
Notice of 43rd Annual General Meeting of the Company scheduled to be held on Wednesday, the September 30, 2026 at 11:00 AM (IST)
BSE9/4/2026material
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report
BSE9/4/2026
Reg. 34 (1) Annual Report.
Annual Report for the FY 2025-26
BSE9/4/2026
Board Meeting Intimation for Fund Raising
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/09/2026 ,inter alia, to consider and approve Fund Raising
BSE9/4/2026material
Press Release / Media Release
Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.
BSE8/25/2026
Press Release / Media Release
Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) Unit
BSE8/21/2026
Investor Presentation
Investor Presentation
BSE8/19/2026
Update on board meeting
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Further to our earlier intimation ....
BSE8/11/2026material
Board Meeting Intimation for Considering Un-Audited Financial Results For The Quarter Ended 30Th June, 2026 And Declare Interim Dividend, If Any
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Un-audited Financial Results for ....
BSE8/6/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.